<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02682810</url>
  </required_header>
  <id_info>
    <org_study_id>12-1346</org_study_id>
    <secondary_id>5U01AI100053-03</secondary_id>
    <nct_id>NCT02682810</nct_id>
  </id_info>
  <brief_title>Point of Care Virologic Testing to Improve Outcomes of HIV-Infected Children</brief_title>
  <official_title>Z 1303 - Point-of-Care Virologic Testing to Improve Outcomes of HIV-Infected Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-arm, unmasked, randomized, controlled trial to test the effectiveness of the
      Alere Q point-of-care (POC) HIV diagnostic assay for use in resource-poor settings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At public sector clinics in Lusaka, Zambia, approximately 4,000 HIV-exposed infants between 4
      and 12 weeks of life will be randomized in this trial of point-of-care virologic testing to
      improve outcomes of HIV-infected children in Zambia. There is a standard of care (SOC) or
      control arm and an intervention arm known as the Alere arm. In both study arms, early infant
      diagnosis (EID) will be provided at 6 weeks of life. Infants randomized to the SOC arm will
      receive EID through the existing prevention of mother-to-child-transmission (PMTCT) program,
      with samples sent to an off-site laboratory for DNA PCR testing. Infants randomized to the
      intervention arm will receive POC diagnostic Alere Q qualitative test (along with a dried
      blood spot [DBS] drawn for confirmatory DNA PCR).

      HIV-infected infants will be followed for 12 months. The acceptability of point-of-care
      testing for EID will also be determined through the use of cross-sectional surveys of
      clinicians, laboratory personnel, and parents/guardians.

      The feasibility will be assessed by a time-in-motion (TIM) and value stream mapping (VSM)
      analyses will also be conducted to compare the Alere Q to two additional testing
      technologies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of HIV-infected children in each arm who remain alive, in care, and with no HIV circulating in their bloodstream 12 months after initial diagnosis</measure>
    <time_frame>time of initial diagnosis through 12 months post diagnosis</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of HIV-infected children who start anti-retroviral therapy (ART) within 6 months of the initial diagnosis</measure>
    <time_frame>time of initial diagnosis through 6 months post diagnosis</time_frame>
    <description>Short-term benefit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of children starting ART who remain in care for 12 months following the initial diagnosis</measure>
    <time_frame>time of initial diagnostic blood draw through 12 months post diagnosis</time_frame>
    <description>Long-term retention benefit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Early Infant HIV Diagnosis</condition>
  <arm_group>
    <arm_group_label>DNA PCR HIV diagnostic test</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SOC or control arm through existing PMTCT program, with DBS samples sent to an off-site laboratory for DNA PCR testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alere Q POC nucleic acid-based platform</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>POC test to provide same-day diagnosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DNA PCR HIV diagnostic test</intervention_name>
    <description>standard of care</description>
    <arm_group_label>DNA PCR HIV diagnostic test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alere Q</intervention_name>
    <description>POC diagnostic Alere Q qualitative test (along with a DBS drawn for confirmatory DNA PCR)</description>
    <arm_group_label>Alere Q POC nucleic acid-based platform</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  4 to 12 weeks of life

          -  documented HIV exposure through seropositive maternal or infant HIV antibody test

          -  with a parent or guardian will and able to provide written informed consent and to
             have the participant followed for 12 months after study enrolment

        Exclusion Criteria:

          -  Infants will be excluded from participation if they have major congenital anomalies or
             other medical conditions that would require management at a referral facility or
             otherwise interfere with study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Stringer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carla Chibwesha, MD, MSc</last_name>
    <email>carla_chibwesha@med.unc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chawama Health Centre</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Chibwesha, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chelstone Health Centre</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Chibwesha, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chilenje Health Centre</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Chibwesha, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chipata Health Centre</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Chibwesha, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kanyama Health Centre</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Chibwesha, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mtendere Health Centre</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Chibwesha, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Zambia</country>
  </location_countries>
  <link>
    <url>http://www.unc.edu</url>
    <description>University of North Carolina website</description>
  </link>
  <reference>
    <citation>Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, Jean-Philippe P, McIntyre JA; CHER Study Team. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008 Nov 20;359(21):2233-44. doi: 10.1056/NEJMoa0800971.</citation>
    <PMID>19020325</PMID>
  </reference>
  <reference>
    <citation>UNAIDS. 2014 Progress Report on The Global Plan: http://www.unaids.org/sites/default/files/documents/JC2681_2014-Global-Plan-progress_en.pdf. Accessed: 01 February 2015.</citation>
  </reference>
  <reference>
    <citation>Stringer EM, Ekouevi DK, Coetzee D, Tih PM, Creek TL, Stinson K, Giganti MJ, Welty TK, Chintu N, Chi BH, Wilfert CM, Shaffer N, Dabis F, Stringer JS; PEARL Study Team. Coverage of nevirapine-based services to prevent mother-to-child HIV transmission in 4 African countries. JAMA. 2010 Jul 21;304(3):293-302. doi: 10.1001/jama.2010.990.</citation>
    <PMID>20639563</PMID>
  </reference>
  <reference>
    <citation>Stringer JS, Sinkala M, Maclean CC, Levy J, Kankasa C, Degroot A, Stringer EM, Acosta EP, Goldenberg RL, Vermund SH. Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia. AIDS. 2005 Aug 12;19(12):1309-15.</citation>
    <PMID>16052086</PMID>
  </reference>
  <reference>
    <citation>World Health Organization. Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access (2010 Revision): http://www.who.int/hiv/pub/paediatric/infants2010/en/index.html Accessed 2011.</citation>
  </reference>
  <reference>
    <citation>Braun M, Kabue MM, McCollum ED, Ahmed S, Kim M, Aertker L, Chirwa M, Eliya M, Mofolo I, Hoffman I, Kazembe PN, van der Horst C, Kline MW, Hosseinipour MC. Inadequate coordination of maternal and infant HIV services detrimentally affects early infant diagnosis outcomes in Lilongwe, Malawi. J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):e122-8. doi: 10.1097/QAI.0b013e31820a7f2f.</citation>
    <PMID>21224736</PMID>
  </reference>
  <reference>
    <citation>Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F; Ghent International AIDS Society (IAS) Working Group on HIV Infection in Women and Children. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 2004 Oct 2-8;364(9441):1236-43.</citation>
    <PMID>15464184</PMID>
  </reference>
  <reference>
    <citation>Laursen L. Point-of-care tests poised to alter course of HIV treatment. Nat Med. 2012 Aug;18(8):1156. doi: 10.1038/nm0812-1156.</citation>
    <PMID>22869167</PMID>
  </reference>
  <reference>
    <citation>UNITAID. HIV/AIDS diagnostic technology landscape.Tech. Rep., WHO, Geneva, Switzerland, 2012.</citation>
  </reference>
  <reference>
    <citation>Jani IV, Meggi B, Mabunda N, Vubil A, Sitoe NE, Tobaiwa O, Quevedo JI, Lehe JD, Loquiha O, Vojnov L, Peter TF. Accurate early infant HIV diagnosis in primary health clinics using a point-of-care nucleic acid test. J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):e1-4. doi: 10.1097/QAI.0000000000000250.</citation>
    <PMID>24933096</PMID>
  </reference>
  <reference>
    <citation>Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med. 1984 Oct-Dec;3(4):409-22.</citation>
    <PMID>6528136</PMID>
  </reference>
  <reference>
    <citation>Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, Bwakura-Dangarembizi M, Chi BH, Musoke P, Kamthunzi P, Schimana W, Purdue L, Eshleman SH, Abrams EJ, Millar L, Petzold E, Mofenson LM, Jean-Philippe P, Violari A. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med. 2010 Oct 14;363(16):1510-20. doi: 10.1056/NEJMoa1000931.</citation>
    <PMID>20942667</PMID>
  </reference>
  <reference>
    <citation>Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM, Chi BH, Sinkala M, Kankasa C, Wilson CM, Wilfert CM, Mwango A, Levy J, Abrams EJ, Bulterys M, Stringer JS. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007 Oct 24;298(16):1888-99.</citation>
    <PMID>17954540</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>February 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2016</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>point-of-care HIV diagnosis</keyword>
  <keyword>Alere Q</keyword>
  <keyword>diagnostic</keyword>
  <keyword>children</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

